title: Rosiglitazone does not alter the pharmacokinetics of metformin.
abstract: Rosiglitazone is a potent oral antidiabetic agent of the thiazolidinedione class that works through activation of the peroxisome proliferator-activated nuclear receptor. It improves insulin sensitivity in peripheral tissues and effectively lowers blood glucose in patients with type 2 diabetes. Metformin is a dimethyl-biguanide, also used in type 2 diabetes, that lowers fasting blood glucose primarily by decreasing hepatic glucose output. Rosiglitazone and metformin reduce plasma glucose concentrations via different mechanisms and thus could potentially be used in combination to optimize glycemic control. This study evaluated the effects of the coadministration of these two agents on the pharmacokinetics of both rosiglitazone and metformin. Sixteen male volunteers (22-55 years old) received oral metformin (500 mg every 12 hours), rosiglitazone (2 mg every 12 hours), or the combination each for 4 days. Plasma collected on day 4 of each regimen was assayed for rosiglitazone and metformin concentrations. Oral doses of rosiglitazone and metformin were safe and well tolerated when administered alone or in combination. There were no clinically significant episodes of hypoglycemia or increased blood lactic acid levels following treatment with any regimen. Coadministration of rosiglitazone and metformin had no significant effects on the steady-state pharmacokinetics (AUC(0-12 h), Cmax, tmax, or t1/2) of either drug. The authors conclude that rosiglitazone can be safely administered with metformin and, due to the different mechanisms of action of these agents, may offer a therapeutic advantage in patients with type 2 diabetes mellitus.
authors.affiliation: SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Di Cicco
authors.forename: A
authors.initials: A
authors.lastname: Allen
authors.forename: A
authors.initials: A
authors.lastname: Carr
authors.forename: S
authors.initials: S
authors.lastname: Fowles
authors.forename: D K
authors.initials: DK
authors.lastname: Jorkasky
authors.forename: M I
authors.initials: MI
authors.lastname: Freed
mesh_terms: D000140:Acidosis, Lactic / Q000139:chemically induced; D000328:Adult; D018592:Cross-Over Studies; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics*; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D000077154:Rosiglitazone; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D045162:Thiazolidinediones
chemical_list: D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin